Impulse Dynamics Announces Publication of Data from FIX-HF-5C2 Study Evaluating the Two-Lead Optimizer System

by Impulse Dynamics | Apr 14, 2020 | Press Releases

Availability of the two-lead device represents a significant advancement in the development of cardiac contractility modulation therapy for patients with heart failure MT. LAUREL, N.J.– April 14, 2020 – Impulse Dynamics, a medical device company dedicated to improving...

Impulse Dynamics Announces First Enrollment in Post-Approval Study of CCM Therapy Delivered by the Optimizer System

by Impulse Dynamics | Mar 17, 2020 | Press Releases

Post-Approval Study will evaluate real-world safety and efficacy evidence for breakthrough heart failure therapy MOUNT LAUREL, N.J. – March 17, 2020  Impulse Dynamics, Inc., a company dedicated to improving the lives of people with heart failure, today announced the...

Clinical Registry Data and recently published FIX-HF-5C were presented at the Late-Breaking Clinical Trial Session at EHF 2018

by Impulse Dynamics | May 28, 2018 | Press Releases

Stuttgart, Germany, May 28th, 2018 – Impulse Dynamics Germany, GmbH announced results on “Real World” experience from its European Clinical Registry. The results were presented today by Prof. Gerd Hasenfuß, MD, Professor of Internal Medicine and Director of the Heart...

FIX-HF-5C Late-Breaking Clinical Trial Data Presented at HRS 2018 with Simultaneous Publication in the JACC: Heart Failure

by Impulse Dynamics | May 10, 2018 | Press Releases

Orangeburg, New York, May 10, 2018 – Impulse Dynamics (USA), Inc. announced results from its FIX-HF-5C randomized, Controlled Trial of Cardiac Contractility Modulation in Heart Failure. The study results were presented by Prof. William Abraham, MD, Professor of...